Frequency of CYP2C9 polymorphisms in polynesian people and potential relevance to management of gout with benzbromarone - 12/04/14
, Mary C. Wallace a, Daniel F.B. Wright b, Murray Cadzow c, Nicola Dalbeth d, Peter B. Jones d, Lisa K. Stamp e, Andrew A. Harrison f, Michael A. Black c, Tony R. Merriman cBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
Gout is a major health problem in Polynesians and allopurinol, the drug of choice for the management gout, appears to be less effective in Polynesian patients. The uricosuric drug benzbromarone is an alternative treatment but CYP2C9 poor metabolisers (PMs) may be at a heightened risk of benzbromarone-induced hepatotoxicity. The objectives of this study were to determine the frequency of the PM alleles CYP2C9*2 and CYP2C9*3 in New Zealand (NZ) Caucasian and Polynesian gout cohorts; and then to test for novel CYP2C9 polymorphisms in Polynesians.
Methods |
Eight hundred and fifty-two Caucasians (537 controls, 315 gout patients) and 1072 Māori and Pacific Island (Polynesian) people (620 controls, 452 gout patients) were genotyped for CYP2C9*2 and CYP2C9*3. Forty Polynesians were screened for novel CYP2C9 polymorphisms using whole genome sequencing.
Results |
Frequency of CYP2C9 PM alleles was significantly higher in Caucasians compared to Polynesians (CYP2C9*2: 13.5% versus 3.1%; CYP2C9*3: 5.5% versus 1.6%, P<1.2E-11). Within Polynesians, CYP2C9 PM alleles were rarer in Western Polynesians (Samoa, Tonga) than Eastern Polynesians (NZ and Cook Island Maori; CYP2C9*2: 0.6% versus 2.5%; CYP2C9*3: 0.4% versus 2.0%; P<0.03). A total of 152 SNPs were found by sequencing. None of these variants were predicted by in silico analysis to significantly impact on CYP2C9 expression or activity.
Conclusion |
Prospective CYP2C9 genotyping of Caucasian gout patients may be warranted for benzbromarone, whereas the low frequencies of CYP2C9 PM alleles in Polynesians suggests that the CYP2C9 polymorphism may be of little or no relevance to benzbromarone prescribing in this population.
Le texte complet de cet article est disponible en PDF.Keywords : CYP2C9 poor metabolizer allele, Hepatotoxicity, Uricosuric agent
Plan
Vol 81 - N° 2
P. 160-163 - mars 2014 Retour au numéro
Article précédent
- The learning curve of nurses for the assessment of swollen and tender joints in rheumatoid arthritis
- Peter P. Cheung, Maxime Dougados, Vincent Andre, Nathalie Balandraud, Gérard Chalès, Isabelle Chary-Valckenaere, Emmanuelle Dernis, Ghislaine Gill, Melanie Gilson, Sandrine Guis, Gael Mouterde, Stephan Pavy, Francois Pouyol, Thierry Marhadour, Pascal Richette, Adeline Ruyssen-Witrand, Martin Soubrier, Minh Nguyen, Laure Gossec
- Cardiovascular risk assessment according to a national calibrated score risk index in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors
- José Luis Rosales Alexander, Jesús Cantero-Hinojosa, Juan Salvatierra, César Magro Checa, Miguel Ángel González-Gay, Enrique Raya Álvarez
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?